Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Mitochondrion ; 70: 103-110, 2023 05.
Article in English | MEDLINE | ID: covidwho-2290776

ABSTRACT

Liver damage is a common sequela of COVID-19 (coronavirus disease 2019), worsening the clinical outcomes. However, the underlying mechanism of COVID-induced liver injury (CiLI) is still not determined. Given the crucial role of mitochondria in hepatocyte metabolism and the emerging evidence denoting SARS-CoV-2 can damage human cell mitochondria, in this mini-review, we hypothesized that CiLI happens following hepatocytes' mitochondrial dysfunction. To this end, we evaluated the histologic, pathophysiologic, transcriptomic, and clinical features of CiLI from the mitochondria' eye view. Severe acute respiratory syndrome coronavirus 2 (SARS­CoV­2), the causative agent of COVID-19, can damage hepatocytes through direct cytopathic effects or indirectly after the profound inflammatory response. Upon entering the hepatocytes, the RNA and RNA transcripts of SARS-CoV-2 engages the mitochondria. This interaction can disrupt the mitochondrial electron transport chain. In other words, SARS-CoV-2 hijacks the hepatocytes' mitochondria to support its replication. In addition, this process can lead to an improper immune response against SARS-CoV-2. Besides, this review outlines how mitochondrial dysfunction can serve as a prelude to the COVID-associated cytokine storm. Thereafter, we indicate how the nexus between COVID-19 and mitochondria can fill the gap linking CiLI and its risk factors, including old age, male sex, and comorbidities. In conclusion, this concept stresses the importance of mitochondrial metabolism in hepatocyte damage in the context of COVID-19. It notes that boosting mitochondria biogenesis can possibly serve as a prophylactic and therapeutic approach for CiLI. Further studies can reveal this notion.


Subject(s)
COVID-19 , Chemical and Drug Induced Liver Injury, Chronic , Liver Diseases , Male , Humans , COVID-19/metabolism , SARS-CoV-2 , Chemical and Drug Induced Liver Injury, Chronic/metabolism , Mitochondria/metabolism , RNA
2.
Toxics ; 10(12)2022 Dec 17.
Article in English | MEDLINE | ID: covidwho-2163611

ABSTRACT

Aerosols carrying the virus inside enclosed spaces is an important mode of transmission for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as supported by growing evidence. Urban subways are one of the most frequented enclosed spaces. The subway is a utilitarian and low-cost transit system in modern society. However, studies are yet to demonstrate patterns of viral transmission in subway heating, ventilation, and air conditioning (HVAC) systems. To fill this gap, we performed a computational investigation of the airflow (and associated aerosol transmission) in an urban subway cabin equipped with an HVAC system. We employed a transport equation for aerosol concentration, which was added to the basic buoyant solver to resolve the aerosol transmission inside the subway cabin. This was achieved by considering the thermal, turbulent, and induced ventilation flow effects. Using the probability of encountering aerosols on sampling surfaces crossing the passenger breathing zones, we detected the highest infection risk zones inside the urban subway under different settings. We proposed a novel HVAC system that can impede aerosol spread, both vertically and horizontally, inside the cabin. In the conventional model, the maximum probability of encountering aerosols from the breathing of infected individuals near the fresh-air ducts was equal to 51.2%. This decreased to 3.5% in the proposed HVAC model. Overall, using the proposed HVAC system for urban subways led to a decrease in the mean value of the probability of encountering the aerosol by approximately 84% compared with that of the conventional system.

3.
Cancer Invest ; 40(6): 505-515, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1882885

ABSTRACT

OBJECTIVE: To determine the clinical characteristics and outcomes of COVID-19 in a large cohort of new cancer patients referred to an oncology clinic in the north of Iran. METHODS: During the 20-month COVID-19 pandemic, new cancer patients were followed-up. Demographic, pathologic, and clinical variables were collected for each patient. COVID-19 was confirmed based on a positive polymerase chain reaction test. Analyses were performed using the STATA version 14.0 at a significance level of 0.05. RESULTS: In this study, 1294 new cancer patients were followed for 24 months (mean age: 58.7 years [range 10-95]). During the study period, COVID-19 was diagnosed in 9.4% of the patients with hospitalization rate of 3.4%, an ICU admission rate of 0.7%, and COVID-19 mortality rate of 4.9%. Hematological malignancies (ORU= 2.6, CI95% 1.28-5.34), receiving palliative treatments (ORA=3.03, CI95% 1.6-5.45) and receiving radiotherapy (ORA=2.07, 1.17-3.65) were the most common predictive factors of COVID infection in cancer patients. Also, the COVID mortality was higher in brain cancer patients (p = 0.07), metastatic disease (p = 0.01) and patients receiving palliative treatments (p = 0.02). CONCLUSION: In patients suffering from cancer, COVID-19 infection can be predicted by cancer type, palliative care, and radiotherapy in cancer patients. Furthermore, brain cancers, metastasis, and palliative care were all associated with COVID-19-related mortality.


Subject(s)
COVID-19 , Neoplasms , Adolescent , Adult , Aged , Aged, 80 and over , COVID-19/therapy , Child , Hospitalization , Humans , Iran/epidemiology , Middle Aged , Neoplasms/epidemiology , Neoplasms/therapy , Pandemics , Prospective Studies , SARS-CoV-2 , Young Adult
4.
Asian Pac J Cancer Prev ; 22(1): 19-24, 2021 Jan 01.
Article in English | MEDLINE | ID: covidwho-1052584

ABSTRACT

As of late 2019, the outbreak of novel coronavirus disease (COVID-19) -that started in China- has rapidly afflicted all over the world. The COVID-19 pandemic has challenged health-care facilities to provide optimal care. In this context, cancer care requires special attention because of its peculiar status by including patients who are commonly immunocompromised and treatments that are often highly toxic. In this review article, we have classified the main impacts of the COVID-19 pandemic on oncology practices -followed by their solutions- into ten categories, including impacts on (1) health care providers, (2) medical equipment, (3) access to medications, (4) treatment approaches, (5) patients' referral, (6) patients' accommodation, (7) patients' psychological health, (8) cancer research, (9) tumor board meetings, and (10) economic income of cancer centers. The effective identification and management of all these challenges will improve the standards of cancer care over the viral pandemic and can be a practical paradigm for possible future crises.
.


Subject(s)
COVID-19 , Medical Oncology/organization & administration , Neoplasms/therapy , Humans
5.
Phys Fluids (1994) ; 33(1): 013603, 2021 Jan 01.
Article in English | MEDLINE | ID: covidwho-1039670

ABSTRACT

Jet fans are increasingly preferred over traditional ducted systems as a means of ventilating pollutants in large environments such as underground car parks. The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-which causes the novel coronavirus disease-through the jet fans in underground car parks has been considered a matter of key concern. A quantitative understanding of the propagation of respiratory droplets/particles/aerosols containing the virus is important. However, to date, studies have yet to demonstrate viral (e.g., SARS-CoV-2) transmission in underground car parks equipped with jet fans. In this paper, numerical simulation has been performed to assess the effects of jet fans on the spreading of viruses inside underground car parks.

6.
Int J Radiat Oncol Biol Phys ; 109(4): 859-866, 2021 03 15.
Article in English | MEDLINE | ID: covidwho-957139

ABSTRACT

INTRODUCTION: Radiation therapy (RT), commonly used in cancer management, has been considered as one of the potential treatments for COVID-19 pneumonia. Here, we present the results of the pilot trial evaluating low-dose whole-lung irradiation (LD-WLI) in patients with COVID-19 pneumonia. METHODS: Ten patients with moderate COVID-19 pneumonia were treated with LD-WLI in a single fraction of 0.5 or 1.0 Gy along with the national protocol. The primary endpoint was an improvement in Spo2. The secondary endpoints were the number of days of hospital/intensive care unit stay, the number of intubations after RT, 28-day mortality, and changes in biomarkers. The response rate (RR) was defined as an increase in Spo2 upon RT with a rising or constant trend in the next 2 days, clinical recovery (CR) including patients who were discharged or acquired Spo2 ≥93% on room air, and 28-day mortality rate defined based on days of RT. RESULTS: The median age was 75 years (80% male). Five, 1, and 4 patients received single-dose 0.5 Gy, two-dose 0.5 Gy, and single-dose 1.0 Gy LD-WLI, respectively. The mean improvement in Spo2 at days 1 and 2 after RT was 2.4% (±4.8%) and 3.6% (±6.1%), respectively, with improvement in 9 patients after 1 day. Five, 1, and 4 patients were discharged, opted out of the trial, and died in the hospital, respectively. Two of 5 discharged patients died within 3 days at home. Among discharged patients, the Spo2 at discharge was 81% to 88% in 3 patients and 93% in the other 2 patients. Overall, the RR and CR were 63.6% and 55.5%, respectively. The RR, CR, and 28-day mortality of the single 0.5 Gy and 1.0 Gy WLI groups were 71.4% versus 50% (P = .57), 60% versus 50% (P = .64), and 50% versus 75% (P = .57), respectively. CONCLUSION: LD-WLI with a single fraction of 0.5 Gy or 1 Gy is feasible. A randomized trial with patients who do not receive radiation is required to assess the efficacy of LD-WLI for COVID-19.


Subject(s)
COVID-19/radiotherapy , Lung/radiation effects , Radiation Dosage , Aged , Aged, 80 and over , Female , Humans , Lung/virology , Male , Middle Aged , Pilot Projects , Radiotherapy Dosage , Treatment Outcome
7.
Infect Chemother ; 52(4): 496-502, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-952694

ABSTRACT

To provide a step-by-step approach to chemotherapy (CTx) in the novel coronavirus disease 2019 (COVID-19) era. The COVID-19 pandemic is the current global issue resulting in vast health implications. Amid the COVID-19 era, special attention must be paid to at-risk groups, including patients with cancer. To our knowledge, there is a paucity of data on the decision for CTx during the pandemic. We herein provide practical recommendations on the CTx of cancer patients over the pandemic based on our experience in an educational hospital. The decision on CTx should be considered to be individualized based on clinical findings. We hope that our experience provides a practical guide for clinical oncologists to deliver more effective cancer care over the COVID-19 pandemic.

8.
Rep Pract Oncol Radiother ; 25(5): 765-767, 2020.
Article in English | MEDLINE | ID: covidwho-680687

ABSTRACT

AIM: To provide recommendations for the management of patients with cancer in the COVID-19 era. BACKGROUND: The current global pandemic of COVID-19 has severely impacted global healthcare systems. Several groups of people are considered high-risk for SARS-CoV-2 infection, including patients with cancer. Therefore, protocols for the better management of these patients during this viral pandemic are necessary. So far, several protocols have been presented regarding the management of patients with cancer during the COVID-19 pandemic. However, none of them points to a developing country with limited logistics and facilities. METHODS: In this review, we have provided a summary of recommendations on the management of patients with cancer during the COVID-19 pandemic based on our experience in Shohada-e Tajrish Hospital, Iran. RESULTS: We recommend that patients with cancer should be managed in an individualized manner during the COVID-19 pandemic. CONCLUSIONS: Our recommendation provides a guide for oncology centers of developing countries for better management of cancer.

9.
Int J Radiat Oncol Biol Phys ; 108(5): 1134-1139, 2020 12 01.
Article in English | MEDLINE | ID: covidwho-662636

ABSTRACT

PURPOSE: The COVID-19 outbreak is affecting people worldwide. Many infected patients have respiratory involvement that may progress to acute respiratory distress syndrome. This pilot study aimed to evaluate the clinical efficacy of low-dose whole-lung radiation therapy in patients with COVID-19 pneumonia. METHODS AND MATERIALS: In this clinical trial, conducted in Iran, we enrolled patients with COVID-19 who were older than 60 years and hospitalized to receive supplementary oxygen for their documented pneumonia. Participants were treated with whole-lung irradiation in a single fraction of 0.5 Gy plus the national protocol for the management of COVID-19. Vital signs (including blood oxygenation and body temperature) and laboratory findings (interleukin-6 and C-reactive peptide) were recorded before and after irradiation. RESULTS: Between May 21, 2020 and June 24, 2020, 5 patients received whole-lung irradiation. They were followed for 5 to 7 days to evaluate the response to treatment and toxicities. The clinical and paraclinical findings of 4 of the 5 patients (patient 4 worsened and died on day 3) improved on the first day of irradiation. Patient 3 opted out of the trial on the third day after irradiation. The mean time to discharge was 6 days for the other 3 patients. No acute radiation-induced toxicity was recorded. CONCLUSIONS: With a response rate of 80%, whole-lung irradiation in a single fraction of 0.5 Gy had encouraging results in oxygen-dependent patients with COVID-19 pneumonia.


Subject(s)
COVID-19/radiotherapy , SARS-CoV-2 , Aged , Aged, 80 and over , Female , Humans , Iran , Lung/radiation effects , Male , Middle Aged , Pilot Projects , Radiotherapy Dosage , Treatment Outcome
10.
J Gastrointest Cancer ; 51(3): 800-804, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-640099

ABSTRACT

PURPOSE: Today, the rapid outbreak of COVID-19 is the leading health issue. Patients with cancer are at high risk for the development of morbidities of COVID-19. Hence, oncology centers need to provide organ-based recommendations for optimal management of cancer in the COVID-19 era. METHODS: In this article, we have provided the recommendations on management of locally advanced rectal cancer during the COVID-19 pandemic based on our experience in Shohada-e Tajrish Hospital, Iran. RESULTS: We recommend that patients with locally advanced rectal cancer should be managed in an individualized manner in combination with local conditions related to COVID-19. CONCLUSION: Our recommendation may provide a guide for oncology centers of developing countries for better management of locally advanced rectal cancer.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/prevention & control , Medical Oncology/standards , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Practice Guidelines as Topic/standards , Rectal Neoplasms/therapy , Age Factors , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/standards , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Betacoronavirus/isolation & purification , COVID-19 , Chemotherapy, Adjuvant/standards , Clinical Decision-Making , Consensus , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Coronavirus Infections/virology , Humans , Infection Control/standards , Iran/epidemiology , Medical Oncology/methods , Neoadjuvant Therapy/standards , Neoplasm Staging , Palliative Care/methods , Palliative Care/standards , Patient Selection , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Pneumonia, Viral/virology , Proctectomy/standards , Rectal Neoplasms/pathology , Rectum/pathology , Rectum/surgery , SARS-CoV-2
11.
Med Hypotheses ; 140: 109762, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-101985

ABSTRACT

On March 11, 2020, the World Health Organization declared the coronavirus outbreak a pandemic. Since December 2019, the world has experienced an outbreak of coronavirus disease 2019 (COVID-19). Epidemiology, risk factors, and clinical characteristics of patients with COVID-19 have been reported but the factors affecting the immune system against COVID-19 have not been well described. In this article, we provide a novel hypothesis to describe how an increase in cellular adenosine triphosphate (c-ATP) can potentially improve the efficiency of innate and adaptive immune systems to either prevent or fight off COVID-19.


Subject(s)
Adenosine Triphosphate/immunology , Coronavirus Infections/immunology , Immune System , Pneumonia, Viral/immunology , Aged , Apoptosis , Betacoronavirus , COVID-19 , Comorbidity , Cytokines/immunology , Female , Humans , Interferons/immunology , Male , Models, Theoretical , Pandemics , Prognosis , SARS-CoV-2 , Sex Factors , Smoking , T-Lymphocytes/immunology , Tobacco Use Disorder/complications
12.
Asian Pac J Cancer Prev ; 21(3): 569-573, 2020 Mar 01.
Article in English | MEDLINE | ID: covidwho-18788

ABSTRACT

Coronavirus outbreak has affected thousands of people in at least 186 countries which has affected the cancer care delivery system apart from affecting the overall health system. Cancer patients are more susceptible to coronavirus infection than individuals without cancer as they are in an immunosuppressive state because of the malignancy and anticancer treatment. Oncologists should be more attentive to detect coronavirus infection early, as any type of advanced cancer is at much higher risk for unfavorable outcomes. Oncology communities must ensure that cancer patients should spend more time at home and less time out in the community. Oncologists and other health care professionals involved in cancer care have a critical opportunity to communicate to their patients to pass on right information regarding practice modifications in view of COVID-19 outbreaks. Countries must isolate, test, treat and trace to control the coronavirus pandemic. There is a paucity of information on novel coronavirus infection and its impact on cancer patients and cancer care providers. To date, there is no scientific guideline regarding management of cancer patients in a background of coronavirus outbreak.
.


Subject(s)
Betacoronavirus/physiology , Coronavirus Infections/prevention & control , Delivery of Health Care , Disease Outbreaks , Neoplasms/complications , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Humans , Immunosuppression Therapy , Pneumonia, Viral/complications , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL